An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Guardant Health Announces Partnership with Epic to Streamline Access to Company’s Broad Portfolio of Cancer Tests
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
partnership
Rhea-AI Summary
Guardant Health has announced a partnership with Epic, enhancing access to its cancer tests for over 250 million patients. This integration allows healthcare providers to electronically order Guardant tests, including Guardant SHIELD for colorectal cancer screening, and access results seamlessly. The collaboration aims to simplify workflows for clinicians, improving patient care by ensuring quick access to critical test results. The integration is expected to be completed in Q3 2023, promoting the adoption of Guardant's precision oncology offerings across diverse healthcare settings.
Positive
Partnership with Epic enhances access to cancer tests for over 250 million patients.
Integration allows healthcare providers to electronically order tests and access results directly.
Expected completion of integration in Q3 2023 will streamline clinical workflows.
Negative
None.
Partnership will Make Guardant Health Cancer Tests Available to Over 250 Million Patients with a Record in Epic
Integration Will Simplify the Process for Clinicians to Order Tests and Access Results Directly in the Patient Record
REDWOOD CITY, Calif.--(BUSINESS WIRE)--
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with Epic, the nation’s most widely used comprehensive health record, to integrate the company’s broad portfolio of cancer tests with Epic. This integration will make it easier for health systems, community healthcare providers and retail health clinics to make Guardant Health blood tests part of routine clinical care by providing direct ordering access and results delivery.
“This partnership will allow us to provide a best-in-class customer experience for healthcare providers to easily order Guardant Health tests and access results quickly, giving them more time to focus on their patients,” said Helmy Eltoukhy, Guardant Health co-CEO. “We are committed to providing the highest quality service to healthcare professionals, and the integration of our tests with Epic, which will include Guardant SHIELD™, our blood test to screen for early signs of colorectal cancer, will help to increase the scale and adoption of our offerings in both community practices and large health systems.”
Clinicians will be able to order Guardant Health tests electronically within Epic once the integration is complete in the third quarter of this year. In addition to Guardant SHIELD, clinicians will be able to order current flagship tests such as Guardant360® CDx and Guardant360 Response™ to help physicians inform treatment decisions for patients with advanced cancer, and Guardant Reveal™ to detect residual and recurrent disease in patients with early-stage cancer. This integration will ensure healthcare providers have easy access to test results and health information in one single, secure place so that they can quickly make informed treatment decisions for their patients.
“Our shared commitment to healthcare innovation makes this partnership a natural fit that will benefit clinicians and patients alike,” said Alan Hutchison, vice president of population health at Epic. “Guardant Health’s integration with Epic will provide an easier and more efficient workflow for clinicians to order cancer tests and access real-time results, giving providers the information they need to make the best care decision for their patients.”
ABOUT GUARDANT HEALTH
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2021, and any current and periodic reports filed with the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
What is the significance of Guardant Health's partnership with Epic?
The partnership integrates Guardant Health's cancer tests into Epic, potentially enhancing access to over 250 million patients and improving clinical workflows.
When will the integration of Guardant Health's tests with Epic be completed?
The integration is expected to be completed in the third quarter of 2023.
What tests will be available through the Epic integration?
Clinicians will be able to order tests including Guardant SHIELD for colorectal cancer and Guardant360 for advanced cancer treatment decisions.
How will the Epic integration impact patient care?
The integration aims to simplify the test ordering process and provide quick access to results, thereby enhancing decision-making in patient care.
